Maraviroc(mar ah vye’ rock)
CelsentriDNC (CAN), SelzentryDNC
PREGNANCY CATEGORY B
Drug Classes
Antiviral
CCR5 coreceptor antagonist
Therapeutic Actions
Selectively binds to the human chemokine receptor CCR5 on the cell membrane, preventing interaction of HIV-1 and CCR5 needed for HIV to enter the cell and multiply.
Indications
-
Combination antiretroviral treatment of adults infected only with detectable CCR5-tropic HIV-1
Contraindications and Cautions
-
Contraindicated with hypersensitivity to any component of the drug, lactation.
-
Use cautiously with coinfection with hepatitis B, liver disease, increased risk of CV events, hypotension, skin and hypersensitivity reactions, renal impairment, pregnancy.
Available Forms
TabletsDNC—150, 300 mg
Dosages
Adults
When given with strong CYP3A inhibitors, protease inhibitors (except tipranavir/ritonavir), delavirdine, 150 mg PO bid. When given with tipranavir/ritonavir, nevirapine, enfuvirtide, nucleoside reverse transcriptase inhibitors, other drugs that are not strong CYP3A inhibitors, 300 mg PO bid. When given with efavirenz, rifampin, carbamazepine, phenobarbital, phenytoin, 600 mg PO bid.
Pediatric patients younger than 16 yr
Safety and efficacy not established.
Patients with renal impairment
With potent CYP3A inhibitors: If CrCl ranges from 30–80 mL/min or more, give 150 mg PO bid. With other concomitant medications, give 300 mg PO bid. With CYP3A inducers, give 600 mg PO bid. Drug is not recommended if CrCl is less than 30 mL/min or if patient is on dialysis.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
